Case-Based Learning on Optimal Immuno-Oncologic Management of Extensive-Stage Small Cell Lung Cancer

Program Overview

Small-cell lung cancer is a particularly deadly subtype of lung cancer, which accounts for approximately 15% of new lung cancer diagnoses. Unfortunately, nearly 60% of patients with SCLC present first with metastatic or extensive-stage (ES) disease, for whom standard of care therapy for nearly 40 years has been platinum doublet chemotherapy (cisplatin or carboplatin combined with etoposide or irinotecan), with or without prophylactic cranial irradiation. While generally achieving high response rates, relapse after this therapy has proven to be routine and rapid, resulting in a typical progression-free survival of less than 6 months and median overall survival of less than 9 months. Chemo-immunotherapy evolved to become the standard of care for ES-SCLC, but the improvement in survival, though significant compared to platinum doublet chemotherapy, has remained modest. More recent trials are evaluating newer agents and a more rational, biomarker- based delivery of those agents.

Strategies using targeted immune oncology (such as atezolizumab or durvalumab) in combination with carboplatin, etoposide, or cisplatin, for example, have become first-line treatment in ES-SCLC and offer improved overall survival. Education about these strategies is important for the many stakeholders who contribute to the management of individuals with ES-SCLC, including medical oncologists, pulmonologists, hospitalists and other internists, oncology nurse navigators, and oncology specialty pharmacists. Early initiation and individualization of care, along with optimization of communication and collaboration among the members of the multidisciplinary oncology team, are likely to have the greatest potential impact on patient outcomes. These expert-led live streamed town hall meetings, each focused on one of those key constituencies in the management of ES-SCLC, aim to improve care and patient outcomes by familiarizing clinicians with the most current actionable data and guidelines.

Target Audience

Community-based medical oncologists. pulmonologists, hospitalists, internists, oncology nurse navigators, oncology APPs, federal practitioners, and other healthcare professionals who care for patients with ES-SCLC.

Agenda

Session 1: Community medical oncologists and their supporting APPs – Sandip Patel, MD and Nicolas Girard, MD

Session 2: Pulmonologists, hospitalists, and their supporting APPs – Sandip Patel, MD; George Cheng, MD, PhD; and Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T)

Session 3: Oncology nurse navigators – Sandip Patel, MD; Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); and Nicolas Girard, MD

Learning Objectives

Review the epidemiology and natural history of ES-SCLC, and the biologic basis of these tumors’’ potential response to immune-oncologic therapy.
Review, analyze, and contextualize current treatment guidelines for first-line therapy for ES-SCLC and clinical trial data that underpin those recommendations.
Discuss the mechanism of action, tolerability, and practical use considerations of deploying immune-oncologic therapy in patients with ES-SCLC.
Develop individualized strategies to treat and support patients with ES-SCLC, with particular attention to the presence or absence of brain metastases, barriers to healthcare, and optimal functioning of the multidisciplinary and interprofessional healthcare team.
Update healthcare providers who manage patients with ES-SCLC on new and emerging treatment approaches aimed at improving outcomes for patients with ES-SCLC.

Faculty

Sandip Pravin Patel, MD (Course Chair)
Professor, Medical Oncology
Leader, Experimental Therapeutics
Deputy Director, San Diego Center for Precision Immunotherapy
University of California San Diego
San Diego, California

George Cheng, MD, PhD
Director of Interventional Pulmonology, Bronchoscopy, and Pleural Disease
Director of Interventional Pulmonology Fellowship
University of California San Diego
San Diego, California

Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T)
Thoracic Oncology Nurse Navigator
Community Healthcare System
Munster, Indiana

Nicolas Girard, MD, PhD
Professor of Respiratory Medicine
Versailles Saint Quentin University
Professor, Head, the Curie-Montsouris Thorax Institute
Institut Curie
Université Paris-Saclay
Paris, France

Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty	Relationship Identified With:
Sandip Patel, MD	*Consultant/Advisor:* Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Certis USA L.L.C.; Lilly; Jazz Pharmaceuticals, Inc.; Genentech, Inc.; Illumina, Inc.; Merck & Co., Inc.; Pfizer Inc.; Rakuten Medical Inc.; Tempus *Grant/Research Support:* Amgen Inc.; AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; Fate Therapeutics; Gilead Sciences, Inc.; Iovance Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; Pfizer Inc.; SQZ Biotechnologies Company
George Cheng, MD, PhD	*Consultant/Advisor: Boston Scientific Corporation; Intuitive Pharma; Medtronic; Olympus Corporation; Pinnacle Biologics, Inc.; restor3d (co-founder) Grant/Research Support*: Body Vision Medical, Ltd.; Intuitive Surgical; Lung Therapeutics
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T)	Nothing to disclose
Nicolas Girard, MD, PhD	*Consultant/Advisor:* AbbVie Inc.; Amgen Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Daiichi Sankyo Company Limited; F. Hoffman-La Roche; Ipsen Pharma; Janssen Global Services, LLC; LEO Pharma; Novartis AG; Merck & Co., Inc.; Pfizer Inc.; Sanofi; Takeda Pharmaceutical Company Limited *Grant/Research Support:* Amgen Inc.; AstraZeneca; AbbVie Inc.; BeiGene, Inc.; Bristol Myers Squibb; Boehringer Ingelheim International; Daiichi Sankyo Company Limited; F. Hoffman-La Roche; Gilead Sciences, Inc.; Janssen Global Services, LLC; LEO Pharma; Lilly; Merck Merck & Co., Inc.; Novartis AG; Shiva Pharmachem LTD.

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of up to 3.0 AMA PRA Category 1 Credits^TM.
AcademicCME designates this enduring material for a maximum of up to 3 CNE Contact Hours.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
Complete the Pre-Activity Questions
Read or Review the activity content.
Complete the Post-Activity Test Questions and Evaluation.
Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).

CME and CNE credit will be issued appropriate certificate of completion.
Others may request a “certificate of completion”.

Learners should claim only the credit commensurate with the extent of their participation in the activity.